Engage with Vetter’s clinical and commercial teams for the highly customized, intensive work and technology needed to efficiently transfer manufacturing processes and analytical methods.
Tech transfers take place at numerous critical points in the product life cycle, both between drug owners and external partners and between partner teams and facilities. They can be a back-up strategy for risk management, a strategic step to build an adequate market supply, or a resource and capacity management effort. No matter the reason, the tech transfer is a crucial process - one that requires a partner with the experience and expertise to get it right from the start.
At Vetter, we have both the experience and skill needed to reduce both the risk and complexity involved in the tech transfer process - including starting material testing, new method validation, instrument validation, process qualification, stability testing, and clinical testing. We have a proven track record of successful handoffs, both from our customers to Vetter and between our state-of-the-art facilities.
As a globally acting CDMO with customers around the world, we’ve optimized our services and facilities to support safe, efficient transfers of drug products, processes, and customer intellectual property (IP) between our key sites in Europe and the US - as well as between key phases of the product life cycle.
Analytics, process, and regulatory teams at both our clinical and commercial facilities all share the same quality approach, enabling consistency and continuity from each product life cycle stage to the next.
.
Your next tech transfer may not be as simple as a new batch size: you may be changing delivery systems, service partners, or responsibilities within your supplier network. We have the experience and know-how to help you manage all these multivariate scenarios.
Whether you’re scaling up production, outlicensing to a new partner, or recently acquired a new product, we have seasoned expertise to help you ensure your valuable asset makes a secure transition from each stage of its life cycle to the next.
To protect timelines, cost projections, and regulatory compliance, we partner closely with our customers to develop processes that mirror those at our commercial production facilities.
Henrik Oberle, Vice President Development Service
